AI Article Synopsis

  • Pemigatinib is an FGFR inhibitor approved for treating biliary tract cancer with FGFR2 fusion.
  • A case is reported of a 54-year-old woman with advanced cholangiocarcinoma who developed serious ocular side effects (SRD) after starting pemigatinib.
  • Adjusting the dosage of pemigatinib resulted in the patient's SRD fully recovering while still continuing to see a reduction in tumor size.

Article Abstract

Pemigatinib is a fibroblast growth factor receptor inhibitor (FGFRi) approved for the treatment of patients with previously treated biliary tract cancer with FGFR2 fusion. Although infrequent, ocular toxicity manifested as serous retinal detachment (SRD) has been observed and is regarded as a serious side effect. We herein report the case of a 54-year-old woman with unresectable cholangiocarcinoma-initiated pemigatinib after failure of gemcitabine plus S-1 (GS). Although the patient experienced repeated SRD after pemigatinib, dose interruption and dose reduction of pemigatinib from 13.5 mg to 9 mg, and from 9 mg to 4.5 mg led to complete recovery of SRD, and continued tumor shrinkage.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183291PMC
http://dx.doi.org/10.2169/internalmedicine.0150-22DOI Listing

Publication Analysis

Top Keywords

serous retinal
8
retinal detachment
8
continued tumor
8
pemigatinib
5
favorable management
4
management repeated
4
repeated serous
4
detachment continued
4
tumor response
4
response patient
4

Similar Publications

Purpose: We describe a case of non-traumatic macular hole in a pediatric patient associated with numerous epiretinal lesions throughout the macula.

Methods: A healthy 9-year-old girl presented to retina clinic with several months of blurry vision in the right eye. Clinically, there was a full-thickness macular hole with serous detachment and white epiretinal tufts.

View Article and Find Full Text PDF

Purpose: To report a case of bilateral ocular cryptococcosis in an immunocompetent patient without neurologic findings.

Methods: Case report.

Results: A 30-year-old healthy Caucasian man presented with painless blurred vision in the left eye.

View Article and Find Full Text PDF

Background: Central serous chorioretinopathy (CSC) is marked by serous retinal detachments caused by fluid leakage from the retinal pigment epithelium, often associated with stress, psychiatric disorders and the use of corticosteroids. This study aims to investigate the clinical and systemic characteristics associated with BALAD in patients with CSC, comparing those with and without BALAD to clarify its function as a biomarker of CSC severity and improve diagnostic and treatment approaches.

Purpose: Compare the clinical characteristics, risk factors, and optical coherence tomography (OCT) findings in patients with Central Serous Chorioretinopathy (CSC) with and without Bacillary Layer Detachment (BALAD), and to identify the distinguishing features and associated conditions of CSC with BALAD.

View Article and Find Full Text PDF

Purpose: To report 8 cases of acute intra ocular inflammation (IOI) following intravitreal injections (IVI) of faricimab in patients with age related macular degeneration (AMD), retinal vein occlusion (RVO) and macular neovascularization associated with chronic central serous retinopathy (CSR).

Methods: This is a multicentric retrospective observational case-series. Cases of acute IOI that occurred in 5 different institutions in France and Italy between November 2023 and June 2024 were reported.

View Article and Find Full Text PDF

Bartonella henselae is a Gram-negative bacillus, mainly parasitizing on cats. When a child is scratched by a cat, they may present with the disease symptoms including regional lymphadenopathy, malaise, fever, and splenomegaly, which is known as cat-scratch disease (CSD). Ocular manifestations occur in 5-10% of patients with CSD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!